The benefits of taking GLP-1 agonists seem to outweigh the risks, at least when taken for approved uses, according to an ...

Researchers have found links to multiple new benefits – and new side effects – in a study of weight-loss drugs such as ...

About 140,400 obese patients in Massachusetts were prescribed medications like Wegovy and Zepbound in 2024, a 255 percent ...

Just how much Medicare price negotiations will negatively impact Novo Nordisk, though, depends on what the final negotiated ...

When it comes to medically assisted weight loss, there’s two main schools of thought: either weight loss drugs, like the ...

The MRHA, which overseas the safety of medicines, vaccines and healthcare devices, was accused of not acting fast enough when ...

Two recent disappointing clinical trials of highly-anticipated weight-loss drugs have made it clear that it is too early to ...

It appears an unintended side effect of the drug has now struck some of Britain's known suitmakers, who are fed up with ...

New Rule Seeks to Expand Medicare and Medicaid Coverage of Weight Loss Drugs. The Biden Administration has proposed a new ...

The market for GLP-1 drugs is projected to exceed $200 billion in annual sales by 2031, according to Morningstar Equity Research. Current market leaders include Novo Nordisk NVO and Eli Lilly LLY with ...

Karen Huger revealed whether she's using Ozempic, explaining she's using a medication for a reason other than weight loss. Learn more.

A new study highlighted Monday the potential benefits of popular diabetes drugs on a wide range of health issues including dementia and cardiovascular diseases, although experts warned against seeing ...